BR0312408A - Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) - Google Patents
Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap)Info
- Publication number
- BR0312408A BR0312408A BR0312408-8A BR0312408A BR0312408A BR 0312408 A BR0312408 A BR 0312408A BR 0312408 A BR0312408 A BR 0312408A BR 0312408 A BR0312408 A BR 0312408A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- iap
- smac
- binding peptide
- peptide inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 229940088872 Apoptosis inhibitor Drugs 0.000 title 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 title 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 title 1
- 239000000158 apoptosis inhibitor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 abstract 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39315002P | 2002-07-02 | 2002-07-02 | |
| PCT/EP2003/007005 WO2004005248A1 (en) | 2002-07-02 | 2003-07-01 | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312408A true BR0312408A (pt) | 2005-04-19 |
Family
ID=30115550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312408-8A BR0312408A (pt) | 2002-07-02 | 2003-07-01 | Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060128632A1 (https=) |
| EP (1) | EP1519918A1 (https=) |
| JP (1) | JP4541882B2 (https=) |
| CN (1) | CN100384819C (https=) |
| AU (1) | AU2003249920A1 (https=) |
| BR (1) | BR0312408A (https=) |
| CA (1) | CA2491041A1 (https=) |
| WO (1) | WO2004005248A1 (https=) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1715882A4 (en) * | 2004-01-16 | 2009-04-08 | Univ Michigan | SMAC-PEPTIDOMIMETIKA AND ITS USES |
| CN1953744A (zh) * | 2004-02-05 | 2007-04-25 | 诺瓦提斯公司 | Dna拓扑异构酶抑制剂和iap抑制剂的组合 |
| AU2005228950B2 (en) * | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| DK2253614T3 (da) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| KR100984459B1 (ko) | 2004-07-02 | 2010-09-29 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| DK1836201T4 (da) * | 2004-12-20 | 2013-11-11 | Genentech Inc | Pyrrolidininhibitorer af IAP. |
| MX2007010371A (es) | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| DE102005017116A1 (de) * | 2005-04-13 | 2006-10-26 | Novartis Ag | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| WO2006128455A2 (en) | 2005-05-25 | 2006-12-07 | 2Curex Aps | Compounds modifying apoptosis |
| US8318717B2 (en) | 2005-05-25 | 2012-11-27 | 2Curex | Compounds modifying apoptosis |
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| WO2007048224A1 (en) * | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| CN101374829A (zh) | 2005-12-19 | 2009-02-25 | 健泰科生物技术公司 | Iap的抑制剂 |
| KR20080080131A (ko) | 2005-12-20 | 2008-09-02 | 노파르티스 아게 | Ｉａｐ-억제제와 탁산의 조합물 |
| UA96283C2 (uk) * | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
| WO2008014229A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100143499A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP5452223B2 (ja) * | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| MX2009000824A (es) * | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008045905A1 (en) | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as iap inhibitors |
| AU2007325280B2 (en) | 2006-11-28 | 2011-03-10 | Dana-Farber Cancer Institute, Inc. | Combination of IAP inhibitors and FLT3 inhibitors |
| NZ577150A (en) | 2006-12-19 | 2012-04-27 | Genentech Inc | Imidazopyridine inhibitors of iap |
| EP2074087A2 (en) | 2006-12-21 | 2009-07-01 | Wyeth | Synthesis of pyrrolidine compounds |
| JP5454943B2 (ja) * | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| WO2008134679A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| AU2009203971A1 (en) * | 2008-01-11 | 2009-07-16 | Genentech, Inc. | Inhibitors of IAP |
| JP2011529962A (ja) | 2008-08-02 | 2011-12-15 | ジェネンテック， インコーポレイテッド | Ｉａｐのインヒビター |
| US20110218211A1 (en) * | 2008-08-16 | 2011-09-08 | Genentech, Inc. | Azaindole inhibitors of iap |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| CN105646471A (zh) | 2009-08-12 | 2016-06-08 | 诺华股份有限公司 | 细胞凋亡蛋白抑制剂的固体口服制剂和晶形 |
| EP2478358A1 (en) * | 2009-09-18 | 2012-07-25 | Novartis AG | Biomarkers for iap inhibitor compounds |
| CN102050867A (zh) * | 2009-11-10 | 2011-05-11 | 上海艾力斯医药科技有限公司 | 四肽类似物、制备方法及其应用 |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| BR112017028269A2 (pt) * | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| CN110709096B (zh) | 2017-05-05 | 2023-10-31 | 泽兰德制药公司 | 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用 |
| CN110944719A (zh) * | 2017-07-25 | 2020-03-31 | 合帕吉恩治疗公司 | 凋亡蛋白的二聚肽抑制剂 |
| EP3658158A4 (en) * | 2017-07-27 | 2021-04-14 | The National Institute for Biotechnology in the Negev Ltd. | SMAC / YLDIABLO INHIBITORS TO TREAT CANCER |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| WO2022056368A1 (en) | 2020-09-14 | 2022-03-17 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2025256500A1 (zh) * | 2024-06-11 | 2025-12-18 | 温州玮祎康泽生物科技有限公司 | Xiap e3连接酶作为肿瘤治疗靶点及其靶向化合物的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801012A (en) * | 1996-09-17 | 1998-09-01 | Northwestern University | Methods and compositions for generating angiostatin |
| AU7473500A (en) * | 1999-09-01 | 2001-03-26 | University Of Pittsburgh | Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses |
| US6992063B2 (en) * | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| WO2002030959A2 (en) * | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| DE10105041A1 (de) * | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
-
2003
- 2003-07-01 WO PCT/EP2003/007005 patent/WO2004005248A1/en not_active Ceased
- 2003-07-01 EP EP03762570A patent/EP1519918A1/en not_active Withdrawn
- 2003-07-01 CA CA002491041A patent/CA2491041A1/en not_active Abandoned
- 2003-07-01 CN CNB038156571A patent/CN100384819C/zh not_active Expired - Fee Related
- 2003-07-01 AU AU2003249920A patent/AU2003249920A1/en not_active Abandoned
- 2003-07-01 BR BR0312408-8A patent/BR0312408A/pt not_active IP Right Cessation
- 2003-07-01 US US10/519,042 patent/US20060128632A1/en not_active Abandoned
- 2003-07-01 JP JP2004518651A patent/JP4541882B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-12 US US11/203,370 patent/US20060052311A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100384819C (zh) | 2008-04-30 |
| US20060052311A1 (en) | 2006-03-09 |
| EP1519918A1 (en) | 2005-04-06 |
| JP4541882B2 (ja) | 2010-09-08 |
| CN1665784A (zh) | 2005-09-07 |
| US20060128632A1 (en) | 2006-06-15 |
| CA2491041A1 (en) | 2004-01-15 |
| WO2004005248A1 (en) | 2004-01-15 |
| JP2006501181A (ja) | 2006-01-12 |
| AU2003249920A1 (en) | 2004-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312408A (pt) | Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| BRPI0511350A (pt) | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto | |
| CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| HN2008000949A (es) | Derivados de pirimidinil- aril- urea que son inhibidores de fgf | |
| CR10567A (es) | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap) | |
| GT201100181A (es) | "inhibidores de proteina cinasa" | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| BR0212226A (pt) | Pirrolo pirimidinas como agentes para inibição de cisteìna proteases | |
| BR122018007328B8 (pt) | composto, composição farmaceutica e uso do dito composto | |
| BR0309355A (pt) | 2-(2,6-diclorofenil)-diarilimidazóis | |
| NZ603303A (en) | Peptide epoxyketones for proteasome inhibition | |
| BRPI0519567A2 (pt) | heterociclos tricÍclicos, sua fabricaÇço e uso como agentes farmacÊuticos | |
| MX2009005622A (es) | Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. | |
| BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
| MX2010007948A (es) | Inhibidores de proteinas de apoptosis. | |
| BRPI0411891A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3 | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
| BR0308071A (pt) | Inibidores da protéina farnesil transferase como agentes antitumores | |
| BRPI0413384A (pt) | inibidores da proteìna farnesil transferase como agentes antitumores | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| BRPI0415355A (pt) | triarilimidazóis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 207/08, C07D 207/09, C07D 207/10, C07D 401/12, A61K 31/40, A61P 31/00, A61P 35/00 Ipc: C07D 207/08 (2011.01), C07D 207/09 (2011.01), C07D |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE. |